Ionis Pharmaceuticals (IONS) Status Update summary

Strategic vision and business evolution

• Transitioned from a partner-focused model to a fully integrated commercial-stage biotech, prioritizing independent drug launches and commercialization capabilities.

• Built a scalable commercial organization and strengthened key functions to support late-stage development and commercialization.

• Focused on expanding and diversifying platform technology to maintain leadership in RNA-based therapeutics and drive sustained revenue growth.

• Established key partnerships, notably with AstraZeneca, to accelerate commercial capabilities and global reach.

Pipeline progress and commercial launches

• Achieved three transformational medicine approvals and launched Tryngolza as the first independent commercial product, with additional launches anticipated.

• Ten drugs in phase three development, with a balanced mix of wholly owned and partnered programs targeting neurology and cardiovascular diseases.

• Tryngolza launch for FCS exceeded expectations, with strong patient uptake and over $6 million in first-quarter revenue.

• Olezarsen phase three data for SHTG expected in Q3 2024, with plans for supplemental NDA submission by year-end.

Clinical and technological advancements

• Expanded platform with new chemistries, siRNA, and gene editing, optimizing delivery to new tissues and strengthening neurology and cardiology franchises.

• Demonstrated robust efficacy and safety in pivotal studies, including significant triglyceride reductions and reduced acute pancreatitis events.

• Advanced programs for hereditary angioedema (donidalorsen), ATTR amyloidosis (Wainua), and Lp(a)-driven cardiovascular disease (pelacarsen), with key data readouts and regulatory milestones ahead.

• Ongoing innovation in delivery technologies, including bicycle conjugation and blood-brain barrier penetration for CNS drugs.